INO
Inovio Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.40
+2.94%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +23.5%
- EBIT
- +17.3%
- EPS
- +99.9%
- Free cash flow
- +14.9%
- Operating cash flow
- +15.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +17.4%
- EPS
- +41.2%
Three-year CAGR
- Revenue
- -81.5%
- EBITDA
- +21.2%
- EBIT
- +22.8%
- Net income
- +20.8%
- EPS
- +54.2%
- Free cash flow
- +15.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026